RxDoctor Payments Data

Bret Cornn, PA

Physician Assistant · Seymour, INNPI 1730105768

Payments from drug & device makers

$4,463in general payments, 2019–2025

Across 270 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$769
  • AbbVie$762
  • GSK$406
  • AstraZeneca$329
  • Novartis$264
  • Pfizer$251
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$4,44099%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,463 in reported general payments places this provider in the 90th percentile of 1,955 physician assistant providers in Indiana.

See all physician assistant providers in Indiana

Medicare billing

Part B allowed, 2024
$4,001
Medicare patients
94
Services billed
520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$71,410
EliquisApixaban91$67,525
MounjaroTirzepatide47$56,761
FarxigaDapagliflozin Propanediol43$42,530
TrulicityDulaglutide30$35,376
OzempicSemaglutide34$33,080
XareltoRivaroxaban19$26,931
Teriparatide13$24,412
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$24,071
MyrbetriqMirabegron35$22,344
JardianceEmpagliflozin23$21,829
EntrestoSacubitril/Valsartan20$16,421
CreonLipase/Protease/Amylase12$11,679
Tresiba Flextouch U-100Insulin Degludec19$10,977
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$6,919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$769$92,13777 claims
GSKTrelegy Ellipta, Anoro Ellipta$406$78,329106 claims
PfizerEliquis$251$67,52591 claims
AstraZenecaFarxiga, Breztri Aerosphere$329$66,60073 claims
Novo NordiskOzempic$169$33,08034 claims
Astellas Pharma US IncMyrbetriq$46$22,34435 claims
Boehringer IngelheimJardiance$156$21,82923 claims
NovartisEntresto$264$16,42120 claims
AbbVieCreon$762$11,67912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,955 physician assistant providers in Indiana.

Other physician assistant in Seymour

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →